Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirvetuximab soravtansine in FRα-high recurrent ovarian cancer eligible for platinum-based chemotherapy
2018-004207-39Phase 2Active
- Sponsor
- AGO Research
- Start
- Jan 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of mirvetuximab soravtansine in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by AGO Research. Primary endpoint: Progression-free survival. Started Jan 2021; status: active.
02
Drugs
mirvetuximab soravtansine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2018-004207-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004207-39.